Hetero
Biosimilar developer, India. 5 development products across 5 molecules: adalimumab, bevacizumab, darbepoetin alfa, denosumab, rituximab.
First approval in the Atlas: Jan 2014, Hetero Drugs (INN only), darbepoetin alfa (CDSCO)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved5
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Adalimumab | Mabura | · | · | · | · | Jul 2017 | · |
| Bevacizumab | Hetero bevacizumab | · | · | · | · | May 2016 | · |
| Darbepoetin alfa | Hetero darbepoetin alfa | · | · | · | · | Jan 2014 | · |
| Denosumab | Hetero denosumab | · | · | · | · | Dec 2024 | · |
| Rituximab | Hetero rituximab | · | · | · | · | Mar 2015 | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- CDSCOJan 2014Hetero Drugs (INN only), darbepoetin alfa
- CDSCOMar 2015Hetero Drugs (INN only), rituximab
- CDSCOMay 2016Hetero Drugs (INN only), bevacizumab
- CDSCOJul 2017Mabura, adalimumab
- CDSCODec 2024Hetero Biopharma (INN only), denosumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.